Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Oxytocin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 23 Mar 2018 Planned End Date changed from 30 Mar 2018 to 30 Mar 2019.
- 23 Mar 2018 Planned primary completion date changed from 30 Mar 2018 to 30 Apr 2018.
- 08 May 2017 Status changed from not yet recruiting to recruiting.